Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion. [electronic resource]
Producer: 20160114Description: 918-24 p. digitalISSN:- 1440-1746
- Adult
- Aging -- immunology
- Antiviral Agents -- therapeutic use
- Consolidation Chemotherapy
- Female
- Follow-Up Studies
- Forecasting
- Hepatitis B -- drug therapy
- Hepatitis B e Antigens -- blood
- Humans
- Lamivudine -- therapeutic use
- Male
- Middle Aged
- Molecular Sequence Data
- Nucleotides -- immunology
- Recurrence
- Retrospective Studies
- Risk
- Seroconversion
- Time Factors
- Young Adult
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.